Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week High - Still a Buy?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) reached a new 52-week high during trading on Thursday . The company traded as high as $117.88 and last traded at $113.70, with a volume of 793226 shares trading hands. The stock had previously closed at $115.54.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DNTH. Wedbush boosted their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. HC Wainwright lifted their price objective on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Wall Street Zen raised Dianthus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 9th. Finally, Guggenheim restated a "buy" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Dianthus Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $124.27.

Check Out Our Latest Stock Analysis on DNTH

Dianthus Therapeutics Stock Performance

The stock's 50-day moving average is $99.51 and its two-hundred day moving average is $84.41. The stock has a market cap of $6.22 billion, a PE ratio of -27.40 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. Analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Insider Transactions at Dianthus Therapeutics

In related news, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the transaction, the executive vice president owned 31,249 shares in the company, valued at approximately $3,157,086.47. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Simrat Randhawa sold 26,530 shares of the company's stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the sale, the executive vice president directly owned 4,000 shares in the company, valued at approximately $362,480. The trade was a 86.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 287,084 shares of company stock valued at $29,615,923. 3.02% of the stock is owned by corporate insiders.

Institutional Trading of Dianthus Therapeutics

A number of large investors have recently modified their holdings of DNTH. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Dianthus Therapeutics by 24.8% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 75,396 shares of the company's stock valued at $7,350,000 after acquiring an additional 14,961 shares in the last quarter. Wellington Management Group LLP grew its stake in Dianthus Therapeutics by 24.4% during the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company's stock worth $314,849,000 after purchasing an additional 634,099 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in Dianthus Therapeutics during the 2nd quarter worth about $574,000. Capstone Investment Advisors LLC purchased a new stake in Dianthus Therapeutics during the 2nd quarter worth about $207,000. Finally, Seven Fleet Capital Management LP acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at about $6,309,198,000. Hedge funds and other institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

(Get Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

Read More

• Five stocks we like better than Dianthus Therapeutics
• Bloom Energy’s AI Surge Meets a Valuation Reality Check
• Target Is Winning Shoppers Back—Can the Rally Reach $180?
• IonQ’s Space Contract Points to a New Frontier for Quantum Investors
• Is Apple’s AI Strategy Smarter Than Skeptics Think?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Dianthus Therapeutics Right Now?

Before you consider Dianthus Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.

While Dianthus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here